PTC Therapeutics | PTCT - Sales Revenues



PTC Therapeutics reported $178.9M in Sales Revenues for its fiscal quarter ending in June of 2025.


Sales Change Date
Acadia Pharmaceuticals USD 264.6M 20.28M Jun/2025
Alnylam Pharmaceuticals USD 773.69M 179.5M Jun/2025
Amgen USD 9.18B 1.03B Jun/2025
Biogen USD 2.6B 170M Jun/2025
BioMarin Pharmaceutical USD 825M 80M Jun/2025
Cytokinetics USD 66.76M 65.16M Jun/2025
Daiichi Sankyo JPY 474.6B 44.09B Jun/2025
Gilead Sciences USD 7.1B 430M Jun/2025
Incyte USD 1.06B 10M Jun/2025
Ionis Pharmaceuticals USD 452M 320M Jun/2025
Ironwood Pharmaceuticals USD 85.24M 5.3M Jun/2025
Novartis USD 14.05B 821M Jun/2025
Pfizer USD 14.7B 980M Jun/2025
PTC Therapeutics USD 178.9M 11.1M Jun/2025
Roche Holding CHF 31.64B 883M Dec/2024
Sarepta Therapeutics USD 611.09M 163.81M Jun/2025
TG Therapeutics USD 141.1M 21.4M Jun/2025
Ultragenyx Pharmaceutical USD 166.5M 27.21M Jun/2025
Vertex Pharmaceuticals USD 2.96B 190M Jun/2025
Xencor USD 43.61M 10.88M Jun/2025